Our findings indicate that high-quality habitat that can act as core areas is crucial for spider monkeys. However, just protecting the core areas is not sufficient when planning for spider monkey conservation, especially when their core areas consist of spatially separate nuclei within the home range (Fig. 1). At least in tropical dry forest undergoing regeneration, the matrix between core areas needs to be protected because it contains arboreal routes between critical resources and because barriers to dispersal

would likely reduce population viability in the long term (Laurance, 2004). In addition, non-core areas included a large proportion of mature and last regeneration-stage forest and contained 66% of the food trees (Fig. 1). This means that core areas by themselves were insufficient in providing the minimum nutritional requirement 3Methyladenine for the study community. Furthermore, the level of use an area receives is not necessarily related to its importance during critical periods (Buchanan, Fredrikson & Seaman, 1998). For example, during this study, spider monkeys were observed to drink from two creeks just twice in the driest days of the year (pers. obs.). These water locations were outside the identified

core areas, but they were likely crucial for the see more monkeys’ survival. Thus, although we demonstrated that spider monkeys’ core areas contain critical features and are a key to understand their movement ecology and habitat preferences, conservation initiatives in tropical dry forests need to focus

on larger areas than spatially separate core areas. We thank E. Murillo-Chacon and the staff from Santa Rosa sector, especially R. Blanco and M. M. Chavarria, for their support during field work; M. Luinstra, S. Wilson, A.M. Nuttall, E. Willems, F. Eigenbrod, C. Garcia, L. Maher, M.A. Veganzones and W.Y. Brockelman for valuable input on GIS; A. Douglas and T. Cornulier for insightful discussion; R. Espinoza and A. Guadamuz for botanical assistance; and A.C. Palma and an anonymous reviewer for helpful comments. This study was financially supported by the Leakey Foundation, the North of England Zoological Society and The British Academy. N.A. was supported by the Department of Political medchemexpress Science of the Basque Government (Zientzia Politikarako Zuzendaritza) and the Postdoctoral Fellowship program of Mahidol University, Thailand. Observations complied with current laws in Costa Rica. “
“Physical space is a fundamental habitat constraint for interstitial space-dwelling organisms; however, few studies have examined how physical space variation structures predator/prey interactions within such communities. Streambeds in the western Ozark Plateau are composed of Silurian/Ordovician chert gravel and contain a rich assemblage of interstitial space-dwelling species, including macroinvertebrates, fishes and aquatic salamanders.

Our findings indicate that high-quality habitat that can act as core areas is crucial for spider monkeys. However, just protecting the core areas is not sufficient when planning for spider monkey conservation, especially when their core areas consist of spatially separate nuclei within the home range (Fig. 1). At least in tropical dry forest undergoing regeneration, the matrix between core areas needs to be protected because it contains arboreal routes between critical resources and because barriers to dispersal

would likely reduce population viability in the long term (Laurance, 2004). In addition, non-core areas included a large proportion of mature and last regeneration-stage forest and contained 66% of the food trees (Fig. 1). This means that core areas by themselves were insufficient in providing the minimum nutritional requirement Talazoparib chemical structure for the study community. Furthermore, the level of use an area receives is not necessarily related to its importance during critical periods (Buchanan, Fredrikson & Seaman, 1998). For example, during this study, spider monkeys were observed to drink from two creeks just twice in the driest days of the year (pers. obs.). These water locations were outside the identified

core areas, but they were likely crucial for the NVP-BEZ235 mw monkeys’ survival. Thus, although we demonstrated that spider monkeys’ core areas contain critical features and are a key to understand their movement ecology and habitat preferences, conservation initiatives in tropical dry forests need to focus

on larger areas than spatially separate core areas. We thank E. Murillo-Chacon and the staff from Santa Rosa sector, especially R. Blanco and M. M. Chavarria, for their support during field work; M. Luinstra, S. Wilson, A.M. Nuttall, E. Willems, F. Eigenbrod, C. Garcia, L. Maher, M.A. Veganzones and W.Y. Brockelman for valuable input on GIS; A. Douglas and T. Cornulier for insightful discussion; R. Espinoza and A. Guadamuz for botanical assistance; and A.C. Palma and an anonymous reviewer for helpful comments. This study was financially supported by the Leakey Foundation, the North of England Zoological Society and The British Academy. N.A. was supported by the Department of Political medchemexpress Science of the Basque Government (Zientzia Politikarako Zuzendaritza) and the Postdoctoral Fellowship program of Mahidol University, Thailand. Observations complied with current laws in Costa Rica. “
“Physical space is a fundamental habitat constraint for interstitial space-dwelling organisms; however, few studies have examined how physical space variation structures predator/prey interactions within such communities. Streambeds in the western Ozark Plateau are composed of Silurian/Ordovician chert gravel and contain a rich assemblage of interstitial space-dwelling species, including macroinvertebrates, fishes and aquatic salamanders.

[2] Our results have also shown that the SVR rate was significantly higher in patients with genotype-2 than in genotype-1 patients, but no association between viral load and SVR was found. Platelet counts and the stage of fibrosis have been shown to be other significant predictors of the response to therapy that are independent of IL28B genotype.[20] Neither factor was associated with the virological response in this study. As the recent Japanese guideline recommends examining IL28B genotype and amino acid 70 substitutions in the HCV core

region before treatment,[21] find protocol the core 70 substitution was also analyzed in 10 patients with genotype 1 HCV infection in this study. The mutations had no significant influence on SVR in our patients. Although most of our patients Enzalutamide datasheet tolerate peginterferon and ribavirin well, various side-effects were observed. Symptoms, including fever, lethargy, headache, anorexia and hair loss were common. Three of our patients stopped treatment because of intolerable side-effects. The degree of hair loss in our patients was mild and none of them needed special treatment. Leucopenia was also noted, but dose reduction of peginterferon was not always required. Dose reduction of ribavirin was also not common. Another important side-effect is linear growth

impairment.[22] We have observed linear growth impairment in two patients. It was transient and catch-up growth was observed in both of them. Jonas et al. reported that Peg-IFN-α2a was associated with significant

changes in body weight and linear growth in children, and these effects were generally reversible with cessation of therapy, although height-for-age z scores had not returned to baseline after 2 years of observation in many subjects.[23] The difference in both the frequency and the extent of linear growth impairment between the study of Jonas et al. and ours may be partly due to the proportion of patients who received treatment 48 weeks or longer. In their study 93/107 (87%) subjects received treatment more than 48 weeks; 48 weeks (n = 82) and 72 weeks (n = 11) whereas in our study 16/30 (53%) patients received treatment for 48 weeks and none received 72 上海皓元 week treatment. In conclusion, the present study shows that the IL28B polymorphism is closely associated with the therapeutic effects of PEG-IFN/RBV therapy in pediatric patients with chronic hepatitis C infection. PEG-IFN/RBV therapy may yield good therapeutic effects both in genotype-2 patients and in genotype-1 patients with the IL28B major allele, but the effectiveness may be substantially lower in genotype-1 patients with IL28B minor alleles. Treatment strategy should be carefully implemented in patients with genotype-1 HCV infection who present with IL28B minor alleles.

pylori on Barrett’s esophagus and seven studies that examined the effect of cag A positivity on Barrett’s esophagus. Overall, H. pylori, and even more so cag A, tended to be protective for Barrett’s esophagus in most studies; however, there was obvious heterogeneity across studies. The effect of H. pylori on Barrett’s esophagus varied by geographic location and in the presence of selection and information biases. Only four studies were found without obvious selection and information bias, and these showed a protective effect of H. pylori on Barrett’s esophagus (Relative

risk = 0.46 [95% CI: 0.35, 0.60]). Conclusions:  Estimates for the effect of H. pylori on Barrett’s esophagus were heterogeneous across studies. We identified selection and information bias as potential sources of this heterogeneity. Few Liproxstatin-1 nmr studies without obvious selection and information bias have been conducted to examine the effect of H. pylori on Barrett’s esophagus, but in these, H. pylori infection is associated with a reduced risk of Barrett’s esophagus. “
“The reinfection rate of Helicobacter pylori has been reported to be low in developed countries but high in developing countries.

The aim of this study is to evaluate the long-term reinfection rate of H. pylori and to investigate its RO4929097 mw associated risk factors in South Korea. During 2003–2010, H. pylori-positive 970 patients received standard proton pump inhibitor (PPI)-based triple eradication therapy, and follow-up H. pylori tests were performed with 13C urea breath test or invasive tests (Giemsa histology, CLO test, and culture) 4 weeks after completion of treatment. A total of 331 patients who 上海皓元医药股份有限公司 were maintained an H. pylori-eradicated state at 1 year after eradication were divided into two groups according to reinfection. For the evaluation of risk factors of reinfection, gender, age, smoking, alcohol, income, education, gastrointestinal symptoms, clinical diagnosis, histologic atrophic gastritis or intestinal metaplasia, and clarithromycin resistance were analyzed.

The follow-up period was 18–95 months (mean: 37.1 months), and H. pylori reappeared in 36 of 331 patients (10.9%), resulting in the annual reinfection rate of 3.51% per year. Multivariate analysis showed that male gender (HR 2.28; 95% CI, 1.05–5.00, p = .037) and low monthly family income (≤5000$ vs >5000$) (HR 3.54; 95% CI, 1.08–11.67, p = .038) were associated with H. pylori reinfection. This long-term reinfection rate of H. pylori stayed rather low (3.51% per year), and male and low income determined the reinfection, factors already known to be important for H. pylori infection. “
“Helicobacter pylori (H. pylori) infection is etiologically associated with gastric cancer and peptic ulcer diseases which are both important public health burdens which could be largely eliminated by H. pylori eradication. However, some investigators urge caution based on the hypothesis that eradication of H.

pylori on Barrett’s esophagus and seven studies that examined the effect of cag A positivity on Barrett’s esophagus. Overall, H. pylori, and even more so cag A, tended to be protective for Barrett’s esophagus in most studies; however, there was obvious heterogeneity across studies. The effect of H. pylori on Barrett’s esophagus varied by geographic location and in the presence of selection and information biases. Only four studies were found without obvious selection and information bias, and these showed a protective effect of H. pylori on Barrett’s esophagus (Relative

risk = 0.46 [95% CI: 0.35, 0.60]). Conclusions:  Estimates for the effect of H. pylori on Barrett’s esophagus were heterogeneous across studies. We identified selection and information bias as potential sources of this heterogeneity. Few Selleck Fludarabine studies without obvious selection and information bias have been conducted to examine the effect of H. pylori on Barrett’s esophagus, but in these, H. pylori infection is associated with a reduced risk of Barrett’s esophagus. “
“The reinfection rate of Helicobacter pylori has been reported to be low in developed countries but high in developing countries.

The aim of this study is to evaluate the long-term reinfection rate of H. pylori and to investigate its SAHA HDAC supplier associated risk factors in South Korea. During 2003–2010, H. pylori-positive 970 patients received standard proton pump inhibitor (PPI)-based triple eradication therapy, and follow-up H. pylori tests were performed with 13C urea breath test or invasive tests (Giemsa histology, CLO test, and culture) 4 weeks after completion of treatment. A total of 331 patients who 上海皓元 were maintained an H. pylori-eradicated state at 1 year after eradication were divided into two groups according to reinfection. For the evaluation of risk factors of reinfection, gender, age, smoking, alcohol, income, education, gastrointestinal symptoms, clinical diagnosis, histologic atrophic gastritis or intestinal metaplasia, and clarithromycin resistance were analyzed.

The follow-up period was 18–95 months (mean: 37.1 months), and H. pylori reappeared in 36 of 331 patients (10.9%), resulting in the annual reinfection rate of 3.51% per year. Multivariate analysis showed that male gender (HR 2.28; 95% CI, 1.05–5.00, p = .037) and low monthly family income (≤5000$ vs >5000$) (HR 3.54; 95% CI, 1.08–11.67, p = .038) were associated with H. pylori reinfection. This long-term reinfection rate of H. pylori stayed rather low (3.51% per year), and male and low income determined the reinfection, factors already known to be important for H. pylori infection. “
“Helicobacter pylori (H. pylori) infection is etiologically associated with gastric cancer and peptic ulcer diseases which are both important public health burdens which could be largely eliminated by H. pylori eradication. However, some investigators urge caution based on the hypothesis that eradication of H.

pylori on Barrett’s esophagus and seven studies that examined the effect of cag A positivity on Barrett’s esophagus. Overall, H. pylori, and even more so cag A, tended to be protective for Barrett’s esophagus in most studies; however, there was obvious heterogeneity across studies. The effect of H. pylori on Barrett’s esophagus varied by geographic location and in the presence of selection and information biases. Only four studies were found without obvious selection and information bias, and these showed a protective effect of H. pylori on Barrett’s esophagus (Relative

risk = 0.46 [95% CI: 0.35, 0.60]). Conclusions:  Estimates for the effect of H. pylori on Barrett’s esophagus were heterogeneous across studies. We identified selection and information bias as potential sources of this heterogeneity. Few MAPK inhibitor studies without obvious selection and information bias have been conducted to examine the effect of H. pylori on Barrett’s esophagus, but in these, H. pylori infection is associated with a reduced risk of Barrett’s esophagus. “
“The reinfection rate of Helicobacter pylori has been reported to be low in developed countries but high in developing countries.

The aim of this study is to evaluate the long-term reinfection rate of H. pylori and to investigate its BI-6727 associated risk factors in South Korea. During 2003–2010, H. pylori-positive 970 patients received standard proton pump inhibitor (PPI)-based triple eradication therapy, and follow-up H. pylori tests were performed with 13C urea breath test or invasive tests (Giemsa histology, CLO test, and culture) 4 weeks after completion of treatment. A total of 331 patients who medchemexpress were maintained an H. pylori-eradicated state at 1 year after eradication were divided into two groups according to reinfection. For the evaluation of risk factors of reinfection, gender, age, smoking, alcohol, income, education, gastrointestinal symptoms, clinical diagnosis, histologic atrophic gastritis or intestinal metaplasia, and clarithromycin resistance were analyzed.

The follow-up period was 18–95 months (mean: 37.1 months), and H. pylori reappeared in 36 of 331 patients (10.9%), resulting in the annual reinfection rate of 3.51% per year. Multivariate analysis showed that male gender (HR 2.28; 95% CI, 1.05–5.00, p = .037) and low monthly family income (≤5000$ vs >5000$) (HR 3.54; 95% CI, 1.08–11.67, p = .038) were associated with H. pylori reinfection. This long-term reinfection rate of H. pylori stayed rather low (3.51% per year), and male and low income determined the reinfection, factors already known to be important for H. pylori infection. “
“Helicobacter pylori (H. pylori) infection is etiologically associated with gastric cancer and peptic ulcer diseases which are both important public health burdens which could be largely eliminated by H. pylori eradication. However, some investigators urge caution based on the hypothesis that eradication of H.

A was dosed 100 mg BID and D 60 mg QD. Blood samples for drug assays were drawn during a dosing interval at day 0 (D0) before and 8 weeks (W8) after PR initiation (W8 = 4 weeks after AD initiation). Drugs were assayed by validated LC/MS/MS. Pharmacokinetic (PK) parameters, maximal concentration (Cmax), time to Cmax (Tmax) and predose concentration (Cmin) were Z-VAD-FMK molecular weight observed data; AUC during a dosing interval were estimated by non compartmental method (Win-NonLin®). Results are shown as median and (range).

Geometric mean ratio (GMR) W8/D0 and 90%CI were estimated for RAL parameters. Eighteen of 20 pts were male, median age was 49 (37-59), weight was 74 (65 – 78) kg, CD4 count was 849 (362 – 1994) /mm3, plasma HCV-RNA was 6.11 (4.987.41) log10 UI/mL, and HCV

genotype was 1a in 11 pts and 4 in 9 pts. In addition, 65% were IV drug users, all but 1 pt had plasma HIV-RNA<50 copies/mL, and 7 (35%) had Child A liver cirrhosis. Cmax, Cmin and AUC of A and D at W8 for the 20 pts were 305 (106-1100) ng/mL, 30 (12-144) ng/mL and 1025 (602-3436) ng.h/mL and 1140 (444-2880) ng/mL, 192 (104-641) ng/mL and 12008 (6026-32500) ng.h/mL respectively. For the 7 patients with liver cirrhosis, PK parameters are presented on the table. RAL PK data in the remaining non cirrhotic pts will be presented. All 20 patients had plasma HIV-RNA selleck kinase inhibitor <50 copies/mL at W8. One neutropenia was reported as severe adverse event during the PK study. In conclusion, AD exposure in HIV-HCV co-infected patients was in the same range as in mono-infected patients, and RAL PK remained within a similar range after ADPR initiation in cirrhotic patients despite large inter- and intrapatient PK variabilities as previously reported. Disclosures: Eric Rosenthal - Board Membership: gilead, msd Hugues Aumattre - Speaking and Teaching: BMS, MSD, GS, VIIV, Janssen Francois Bailly - Board Membership: ABBVIE, MSD, BMS, GILEAD; Speaking and Teaching: JANSSEN Jean-Michel Molina - Board Membership: Gilead, BMS, Janssen, merck, Abbott, boehringer; Grant/Research Support: merck; Speaking

medchemexpress and Teaching: merck, gilead, BMS The following people have nothing to disclose: Anne-Marie Taburet, Lionel Piroth, Hubert Paniez, Mélanie Simony, Valerie Furlan, Aurélie Barrail-Tran, Corine Vincent, Eric Billaud, Martine Resch, Laurence Meyer Purpose: Treatment responses to interferon-containing regimens with a protease inhibitor have historically been lower for black patients compared with white patients. The randomized phase 3 PEARL trials evaluated the safety and efficacy of the “3D” regimen of co-formulated ABT-450/ritonavir/ombitasvir and dasabuvir with or without ribavirin (RBV) in HCV genotype (GT) 1b treatment-experienced (PEARL-II) or treatment-naïve (PEARL-III) patients, and in GT1a treatment-naï;ve (PEARL-IV) patients. We assessed treatment response rates based on race or geographic location in a pooled analysis of results from the PEARL trials.

Our data confirmed the genetic heterogeneity of the F9 mutations. Quantitative missense mutations were found to be in different regions of precursor FIX compared with qualitative and combined ones. “
“Regional Haemophilia Treatment Centre, GHE – Louis Pradel Cardiological Hospital, Bron, France

Factor VIII inhibitor bypass activity (FEIBA) is a recommended Ensartinib nmr first-line bypassing agent for bleeding episodes in patients with acquired haemophilia A (AHA). Due to the low incidence of AHA, available clinical data on FEIBA treatment are limited. The study aim was to delineate practice patterns in FEIBA treatment of AHA patients, the haemostatic efficacy of FEIBA, including criteria for its assessment, and safety. A prospective registry was established of AHA patients receiving FEIBA for bleeding episodes or prophylaxis at the time of invasive procedures. Data were collected at 16 participating centres in France. Patients were followed up for 3 months. Haemostatic efficacy, FEIBA regimen and FEIBA-related adverse events were documented. Thirty-four patients averaging 81.8 years old

with standard deviation (SD) 8.1 years were included in the study: 33 for acute bleeding and one for haematoma evacuation. The mean initial dose of FEIBA for acute bleeding was 75.4 U kg−1 (SD, 7.7 U kg−1), most often administered twice daily, and the median duration of FEIBA treatment

was 4.0 days (interquartile range, 2.2–8.0 days). FEIBA was effective in managing 88.0% of bleeding episodes (95% selleck products confidence interval, 75.8–94.5%). No baseline variables influencing treatment response could be identified. The sensitivity and specificity of an objective haemostatic efficacy scale in predicting sequential investigator assessments of haemostatic efficacy were 45.3% and 84.1% respectively. Four patients experienced a total of six serious adverse events possibly related to FEIBA. In the first prospective study specifically focused on FEIBA treatment of patients with AHA, 88.0% of bleeding episodes were effectively managed. “
“This chapter contains sections titled: Introduction Limitations of standard coagulation assays The ideal global coagulation assay Methodologies References “
“Summary.  Data on the clinical manifestations MCE公司 of patients with clotting factor defects other than Haemophilia A, B and von Willebrand disease are limited because of their rarity. Due to their autosomal recessive nature of inheritance, these diseases are more common in areas where there is higher prevalence of consanguinity. There is no previous large series reported from southern India where consanguinity is common. Our aim was to analyze clinical manifestations of patients with rare bleeding disorders and correlate their bleeding symptoms with corresponding factor level.

There are biologically plausible mechanisms that support the causal role of psychological disorders mTOR inhibitor in FGID. Psychological distress, in particular anxiety, can induce aggravation of visceral hyperalgesia as well as

hypervigilance in FGID patients. This leads to poorer quality of life and increased utilization of healthcare service in addition to worsening of symptoms. Despite the numerous reports on the potential therapeutic value of psychotropic agents and psychological intervention, the importance of screening for concomitant psychological disorder in FGID patients has not been fully recognized in daily practice. Most FGID patients tend to have very low awareness of their mood symptoms, which lead to delayed diagnosis, deterioration of disease and

unnecessary investigations. Many of these patients may be reluctant to accept the diagnosis of concomitant psychological disorders and therefore a good doctor-patient rapport and therapeutic relationship are essential for management of these patients. “
“Our aim was to assess the predictive Staurosporine value of liver stiffness (LS), measured by transient elastography (TE), for clinical outcome in human immunodeficiency virus / hepatitis C virus (HIV/HCV)-coinfected patients with compensated liver cirrhosis. This was a prospective cohort study of 239 consecutive HIV/HCV-coinfected patients with a new diagnosis of cirrhosis, done by TE, and no previous decompensation of liver disease. The time from diagnosis to the first liver decompensation and death from liver disease, as well as the predictors of these outcomes, were evaluated. After a median (Q1-Q3) follow-up of 20 (9-34) months, 31 (13%, 95% confidence interval [CI]: 9%-17%) patients developed a decompensation. 上海皓元医药股份有限公司 The incidence of decompensation was 6.7 cases per 100 person-years (95% CI, 4.7-9-6).

Fourteen (8%) out of 181 patients with a baseline LS < 40 kPa developed a decompensation versus 17 (29%) out of 58 with LS ≥ 40 kPa (P = 0.001). Factors independently associated with decompensation were Child-Turcotte-Pugh (CTP) class B versus A (hazard ratio [HR] 7.7; 95% CI 3.3-18.5; P < 0.0001), log-plasma HCV RNA load (HR 2.1; 95% CI 1.2-3.6; P = 0.01), hepatitis B virus coinfection (HR, 10.3; 95% CI, 2.1-50.4; P = 0.004) and baseline LS (HR 1.03; 95% CI 1.01-1.05; P = 0.02). Fifteen (6%, 95% CI: 3.5%-9.9%) patients died, 10 of them due to liver disease, and one underwent liver transplantation. CTP class B (HR 16.5; 95% CI 3.4-68.2; P < 0.0001) and previous exposure to HCV therapy (HR 7.4; 95% CI 1.7-32.4, P = 0.007) were independently associated with liver-related death; baseline LS (HR 1.03; 95% CI 0.98-1.07; P = 0.08) was of borderline significance. Conclusion: LS predicts the development of hepatic decompensations and liver-related mortality in HIV/HCV-coinfection with compensated cirrhosis and provides additional prognostic information to that provided by the CTP score.

There are biologically plausible mechanisms that support the causal role of psychological disorders AUY-922 cell line in FGID. Psychological distress, in particular anxiety, can induce aggravation of visceral hyperalgesia as well as

hypervigilance in FGID patients. This leads to poorer quality of life and increased utilization of healthcare service in addition to worsening of symptoms. Despite the numerous reports on the potential therapeutic value of psychotropic agents and psychological intervention, the importance of screening for concomitant psychological disorder in FGID patients has not been fully recognized in daily practice. Most FGID patients tend to have very low awareness of their mood symptoms, which lead to delayed diagnosis, deterioration of disease and

unnecessary investigations. Many of these patients may be reluctant to accept the diagnosis of concomitant psychological disorders and therefore a good doctor-patient rapport and therapeutic relationship are essential for management of these patients. “
“Our aim was to assess the predictive Dabrafenib value of liver stiffness (LS), measured by transient elastography (TE), for clinical outcome in human immunodeficiency virus / hepatitis C virus (HIV/HCV)-coinfected patients with compensated liver cirrhosis. This was a prospective cohort study of 239 consecutive HIV/HCV-coinfected patients with a new diagnosis of cirrhosis, done by TE, and no previous decompensation of liver disease. The time from diagnosis to the first liver decompensation and death from liver disease, as well as the predictors of these outcomes, were evaluated. After a median (Q1-Q3) follow-up of 20 (9-34) months, 31 (13%, 95% confidence interval [CI]: 9%-17%) patients developed a decompensation. 上海皓元 The incidence of decompensation was 6.7 cases per 100 person-years (95% CI, 4.7-9-6).

Fourteen (8%) out of 181 patients with a baseline LS < 40 kPa developed a decompensation versus 17 (29%) out of 58 with LS ≥ 40 kPa (P = 0.001). Factors independently associated with decompensation were Child-Turcotte-Pugh (CTP) class B versus A (hazard ratio [HR] 7.7; 95% CI 3.3-18.5; P < 0.0001), log-plasma HCV RNA load (HR 2.1; 95% CI 1.2-3.6; P = 0.01), hepatitis B virus coinfection (HR, 10.3; 95% CI, 2.1-50.4; P = 0.004) and baseline LS (HR 1.03; 95% CI 1.01-1.05; P = 0.02). Fifteen (6%, 95% CI: 3.5%-9.9%) patients died, 10 of them due to liver disease, and one underwent liver transplantation. CTP class B (HR 16.5; 95% CI 3.4-68.2; P < 0.0001) and previous exposure to HCV therapy (HR 7.4; 95% CI 1.7-32.4, P = 0.007) were independently associated with liver-related death; baseline LS (HR 1.03; 95% CI 0.98-1.07; P = 0.08) was of borderline significance. Conclusion: LS predicts the development of hepatic decompensations and liver-related mortality in HIV/HCV-coinfection with compensated cirrhosis and provides additional prognostic information to that provided by the CTP score.